Strength of conclusion attained from a clinical trial of thrombolysis will depend considerably on interpretation of changes in end-points other than mortality

1983 ◽  
Vol 74 (1) ◽  
pp. 159
Author(s):  
David H. Spodick
Keyword(s):  
2012 ◽  
Vol 10 (8) ◽  
pp. 989-994 ◽  
Author(s):  
Therese M Heinonen ◽  
Maira Aamer ◽  
Cameron Marshall ◽  
Donald M Black ◽  
Jean-Claude Tardif

2011 ◽  
Vol 7 (4) ◽  
pp. 519-528 ◽  
Author(s):  
Robert J. Mentz ◽  
Christopher M. O’Connor

2018 ◽  
Author(s):  
Julie Ann Sosa

A clinical trial is a planned experiment designed to prospectively measure the efficacy or effectiveness of an intervention by comparing outcomes in a group of subjects treated with the test intervention with those observed in one or more comparable group(s) of subjects receiving another intervention.  Historically, the gold standard for a clinical trial has been a prospective, randomized, double-blind study, but it is sometimes impractical or unethical to conduct such in clinical medicine and surgery. Conventional outcomes have traditionally been clinical end points; with the rise of new technologies, however, they are increasingly being supplemented and/or replaced by surrogate end points, such as serum biomarkers. Because patients are involved, safety considerations and ethical principles must be incorporated into all phases of clinical trial design, conduct, data analysis, and presentation. This review covers the history of clinical trials, clinical trial phases, ethical issues, implementing the study, basic biostatistics for data analysis, and other resources. Figures show drug development and clinical trial process, and type I and II error. Tables list Food and Drug Administration new drug application types, and types of missing data in clinical trials. This review contains 2 highly rendered figures, 2 tables, and 38 references


2019 ◽  
Vol 3 (23) ◽  
pp. 3982-4001 ◽  
Author(s):  
Ann T. Farrell ◽  
Julie Panepinto ◽  
C. Patrick Carroll ◽  
Deepika S. Darbari ◽  
Ankit A. Desai ◽  
...  

Abstract To address the global burden of sickle cell disease (SCD) and the need for novel therapies, the American Society of Hematology partnered with the US Food and Drug Administration to engage the work of 7 panels of clinicians, investigators, and patients to develop consensus recommendations for clinical trial end points. The panels conducted their work through literature reviews, assessment of available evidence, and expert judgment focusing on end points related to: patient-reported outcomes (PROs), pain (non-PROs), the brain, end-organ considerations, biomarkers, measurement of cure, and low-resource settings. This article presents the findings and recommendations of the PROs, pain, and brain panels, as well as relevant findings and recommendations from the biomarkers panel. The panels identify end points, where there were supporting data, to use in clinical trials of SCD. In addition, the panels discuss where further research is needed to support the development and validation of additional clinical trial end points.


2020 ◽  
Vol 95 (8) ◽  
pp. 1578-1580
Author(s):  
Aakash Desai ◽  
Amit Kulkarni ◽  
S. Vincent Rajkumar ◽  
Bishal Gyawali
Keyword(s):  

2012 ◽  
Vol 12 (9) ◽  
pp. 1217-1228 ◽  
Author(s):  
Bartosz Chmielowski ◽  
Noah Federman ◽  
William D Tap

Sign in / Sign up

Export Citation Format

Share Document